Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
ALK-Abelló A/S is a pharmaceutical company engaged in the development and production of allergy immunotherapy products. Based in Hørsholm, Denmark, the company specializes in allergy treatments that include tablets, injections, and drops targeting common allergens such as grass, tree, and ragweed pollen, as well as house dust mites. Established in the early 20th century, ALK-Abelló has expanded its operations to serve markets globally, with a particular focus on Europe and North America. Its strategic advantage lies in its strong research capabilities and a comprehensive portfolio of allergy treatment options. The company's ongoing investment in innovation supports its goal to transform the treatment of allergies worldwide.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
ALK-Abelló A/SJohnson & Johnson
Last price
kr 247.60$273.20
Currency
DKK
USD
kr 55B$658B
40.6041.49
kr 6.10$6.58
0.710.21
kr 1.60$5.28
0.65%1.96%
Sector
HealthHealth
Employees
2,773138,200
Ticker
DKr ALK B$JNJ
Primary listing
CSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in DKrALK B or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.